翰森製藥：葛蘭素史克啓動B7H4 ADC兩項全球三期臨床

醫藥筆記

2025/12/17

▎Armstrong2025年12月16日，葛蘭素史克在Clinicaltrials.gov網站上註冊了B7H4 ADC新藥GSK5733584治療子宮內膜癌、卵巢癌的全球三期臨床試驗，分別計劃入組600例、450例受試者。GSK5733584即葛蘭素史克從翰森製藥引進的HS-20089。翰森製藥B7H4 ADC新藥HS-20089的通用名為Mocertatug rezetecan。HS-...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2592491996"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592491996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592491996?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-12-17 08:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2592491996","market":"hk","top_or_hot":-1,"title":"翰森製藥：葛蘭素史克啓動B7H4 ADC兩項全球三期臨床","media":"醫藥筆記","content":"<div>\n<p>▎Armstrong2025年12月16日，葛蘭素史克在Clinicaltrials.gov網站上註冊了B7H4 ADC新藥GSK5733584治療子宮內膜癌、卵巢癌的全球三期臨床試驗，分別計劃入組600例、450例受試者。GSK5733584即葛蘭素史克從翰森製藥引進的HS-20089。翰森製藥B7H4 ADC新藥HS-20089的通用名為Mocertatug rezetecan。HS-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085055a6ab741c&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>翰森製藥：葛蘭素史克啓動B7H4 ADC兩項全球三期臨床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰森製藥：葛蘭素史克啓動B7H4 ADC兩項全球三期臨床\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">醫藥筆記</strong><span class=\"h-time small\">2025-12-17 08:22</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>▎Armstrong2025年12月16日，葛蘭素史克在Clinicaltrials.gov網站上註冊了B7H4 ADC新藥GSK5733584治療子宮內膜癌、卵巢癌的全球三期臨床試驗，分別計劃入組600例、450例受試者。GSK5733584即葛蘭素史克從翰森製藥引進的HS-20089。翰森製藥B7H4 ADC新藥HS-20089的通用名為Mocertatug rezetecan。HS-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085055a6ab741c&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085055a6ab741c&s=b\">醫藥筆記</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心資產","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085055a6ab741c&s=b","article_id":"2592491996","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217085055a6ab741c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592491996","pubTimestamp":1765930959,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"▎Armstrong2025年12月16日，葛蘭素史克在Clinicaltrials.gov網站上註冊了B7H4 ADC新藥GSK5733584治療子宮內膜癌、卵巢癌的全球三期臨床試驗，分別計劃入組600例、450例受試者。GSK5733584即葛蘭素史克從翰森製藥引進的HS-20089。翰森製藥B7H4 ADC新藥HS-20089的通用名為Mocertatug rezetecan。葛蘭素史克/翰森製藥緊隨其後啓動卵巢癌、子宮內膜癌兩項全球三期臨床。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","03692":"翰森制药","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"Hansoh Pharmaceuticals: GlaxoSmithKline launches two global phase III clinical trials of B7H4 ADC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1.5},"content_text":"▎Armstrong2025年12月16日，葛蘭素史克在Clinicaltrials.gov網站上註冊了B7H4 ADC新藥GSK5733584治療子宮內膜癌、卵巢癌的全球三期臨床試驗，分別計劃入組600例、450例受試者。GSK5733584即葛蘭素史克從翰森製藥引進的HS-20089。翰森製藥B7H4 ADC新藥HS-20089的通用名為Mocertatug rezetecan。HS-20089的氨基酸序列如下，毒素採用恒瑞的SHR-9265（rezetecan），DAR值為4。HS-20089在國內已經獲得卵巢癌突破療法認證。總結阿斯利康AZD8205為首款進入全球三期臨床的B7H4 ADC，採用TOP1i為payload，子宮內膜癌1/2期臨床中表現出優異的療效潛力，ORR為34.6-38.5%，mPFS為7.0個月，安全性方面血液毒性較低，沒有發生副作用導致停藥事件。葛蘭素史克/翰森製藥緊隨其後啓動卵巢癌、子宮內膜癌兩項全球三期臨床。Armstrong技術全梳理系列GPRC5D靶點全梳理；CD40靶點全梳理；CD47靶點全梳理；補體靶向藥物技術全梳理；補體藥物：眼科治療的重要方向；Claudin 6靶點全梳理；Claudin 18.2靶點全梳理；靶點冷暖，行業自知；中國大分子新藥研發格局；被炮轟的「me too」；佐劑百年史；胰島素百年傳奇；CUSBEA：風雨四十載；中國新藥研發的焦慮；中國生物醫藥企業的研發競爭；中國雙抗競爭格局；中國ADC競爭格局；中國雙抗技術全梳理；中國ADC技術全梳理；Ambrx技術全梳理；Vir Biotech技術全梳理；Immune-Onc技術全梳理；亙喜生物技術全梳理；康哲藥業技術全梳理；科濟藥業技術全梳理；愷佧生物技術全梳理；同宜醫藥技術全梳理；百奧賽圖技術全梳理；騰盛博藥技術全梳理；創勝集團技術全梳理；永泰生物技術全梳理；中國抗體技術全梳理；德琪醫藥技術全梳理；德琪醫藥技術全梳理2.0；和鉑醫藥技術全梳理；榮昌生物技術全梳理；再鼎醫藥技術全梳理；藥明生物技術全梳理；恒瑞醫藥技術全梳理；豪森藥業技術全梳理；正大天晴技術全梳理；吉凱基因技術全梳理；基石藥業技術全梳理；百濟神州技術全梳理；百濟神州技術全梳理第2版；信達生物技術全梳理；信達生物技術全梳理第2版；中山康方技術全梳理；復宏漢霖技術全梳理；先聲藥業技術全梳理；君實生物技術全梳理；嘉和生物技術全梳理；志道生物技術全梳理；道爾生物技術全梳理；尚健生物技術全梳理；康寧傑瑞技術全梳理；科望醫藥技術全梳理；岸邁生物技術全梳理；禮進生物技術全梳理；康橋資本技術全梳理；餘國良的抗體藥佈局；荃信生物技術全梳理；安源醫藥技術全梳理；三生國健技術全梳理；仁會生物技術全梳理；樂普生物技術全梳理；同潤生物技術全梳理；宜明昂科技術全梳理；派格生物技術全梳理；邁威生物技術全梳理；Momenta技術全梳理；NGM技術全梳理；普米斯生物技術全梳理；普米斯生物技術全梳理2.0；三葉草生物技術全梳理；貝達藥業抗體藥全梳理；澤璟製藥抗體藥全梳理；恒瑞醫藥抗體藥全梳理；齊魯製藥抗體藥全梳理；石藥集團抗體藥全梳理；豪森藥業抗體藥全梳理；華海藥業抗體藥全梳理；科倫藥業抗體藥全梳理；百奧泰技術全梳理；凡恩世技術全梳理。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}